Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Alterations of HDL particle phospholipid composition and role of inflammation in rheumatoid arthritis.

Giraud C, Tournadre A, Pereira B, Dutheil F, Soubrier M, Lhomme M, Kontush A, Sébédio JL, Capel F.

J Physiol Biochem. 2019 Aug 7. doi: 10.1007/s13105-019-00694-4. [Epub ahead of print]

PMID:
31392628
2.

Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial Infarction.

Sposito AC, de Lima-Junior JC, Moura FA, Barreto J, Bonilha I, Santana M, Virginio VW, Sun L, Carvalho LSF, Soares AAS, Nadruz W, Feinstein SB, Nofer JR, Zanotti I, Kontush A, Remaley AT.

Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1550-1564. doi: 10.1161/ATVBAHA.119.312880. Epub 2019 Jun 13.

PMID:
31189429
3.

Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency.

Zakiev E, Rached F, Lhomme M, Darabi-Amin M, Ponnaiah M, Becker PH, Therond P, Serrano CV Jr, Santos RD, Chapman MJ, Orekhov A, Kontush A.

J Clin Lipidol. 2019 May - Jun;13(3):468-480.e8. doi: 10.1016/j.jacl.2019.02.004. Epub 2019 Feb 25.

PMID:
31003938
4.

HDL-Targeted Therapies During Myocardial Infarction.

Sposito AC, Carmo HR, Barreto J, Sun L, Carvalho LSF, Feinstein SB, Zanotti I, Kontush A, Remaley A.

Cardiovasc Drugs Ther. 2019 Jun;33(3):371-381. doi: 10.1007/s10557-019-06865-1. Review.

PMID:
30778806
5.

Glycosylation of human plasma lipoproteins reveals a high level of diversity, which directly impacts their functional properties.

Sukhorukov V, Gudelj I, Pučić-Baković M, Zakiev E, Orekhov A, Kontush A, Lauc G.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 May;1864(5):643-653. doi: 10.1016/j.bbalip.2019.01.005. Epub 2019 Jan 12.

PMID:
30641224
6.

Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity.

Kayser BD, Lhomme M, Prifti E, Da Cunha C, Marquet F, Chain F, Naas I, Pelloux V, Dao MC, Kontush A, Rizkalla SW, Aron-Wisnewsky J, Bermúdez-Humarán LG, Oakley F, Langella P, Clément K, Dugail I.

FASEB J. 2019 Apr;33(4):4741-4754. doi: 10.1096/fj.201801897R. Epub 2019 Jan 4.

PMID:
30608881
7.

Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes.

Muñoz-Hernandez L, Ortiz-Bautista RJ, Brito-Córdova G, Lozano-Arvizu F, Saucedo S, Pérez-Méndez O, Zentella-Dehesa A, Dauteuille C, Lhomme M, Lesnik P, Chapman MJ, Kontush A, Aguilar Salinas CA.

Atherosclerosis. 2018 Oct;277:72-79. doi: 10.1016/j.atherosclerosis.2018.08.027. Epub 2018 Aug 24.

PMID:
30176567
8.

HDL activates expression of genes stimulating cholesterol efflux in human monocyte-derived macrophages.

Orekhov AN, Pushkarsky T, Oishi Y, Nikiforov NG, Zhelankin AV, Dubrovsky L, Makeev VJ, Foxx K, Jin X, Kruth HS, Sobenin IA, Sukhorukov VN, Zakiev ER, Kontush A, Le Goff W, Bukrinsky M.

Exp Mol Pathol. 2018 Oct;105(2):202-207. doi: 10.1016/j.yexmp.2018.08.003. Epub 2018 Aug 16.

PMID:
30118702
9.

Impact of Lipoproteins on Atherobiology: Emerging Insights.

Feng M, Rached F, Kontush A, Chapman MJ.

Cardiol Clin. 2018 May;36(2):193-201. doi: 10.1016/j.ccl.2017.10.001. Review.

PMID:
29609748
10.

Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches.

Hescot S, Amazit L, Lhomme M, Travers S, DuBow A, Battini S, Boulate G, Namer IJ, Lombes A, Kontush A, Imperiale A, Baudin E, Lombes M.

Oncotarget. 2017 Jul 4;8(66):109924-109940. doi: 10.18632/oncotarget.18968. eCollection 2017 Dec 15.

11.

Intestinal lymphatic HDL miR-223 and ApoA-I are reduced during insulin resistance and restored with niacin.

Mangat R, Borthwick F, Haase T, Jacome M, Nelson R, Kontush A, Vine DF, Proctor SD.

FASEB J. 2018 Mar;32(3):1602-1612. doi: 10.1096/fj.201600298RR. Epub 2018 Jan 3.

PMID:
29183962
12.

Small dense HDLs display potent vasorelaxing activity, reflecting their elevated content of sphingosine-1-phosphate.

Perségol L, Darabi M, Dauteuille C, Lhomme M, Chantepie S, Rye KA, Therond P, Chapman MJ, Salvayre R, Nègre-Salvayre A, Lesnik P, Monier S, Kontush A.

J Lipid Res. 2018 Jan;59(1):25-34. doi: 10.1194/jlr.M076927. Epub 2017 Nov 17.

13.

Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.

Brites F, Martin M, Guillas I, Kontush A.

BBA Clin. 2017 Aug 19;8:66-77. doi: 10.1016/j.bbacli.2017.07.002. eCollection 2017 Dec. Review.

14.

Paradoxical coronary artery disease in humans with hyperalphalipoproteinemia is associated with distinct differences in the high-density lipoprotein phosphosphingolipidome.

Hancock-Cerutti W, Lhomme M, Dauteuille C, Lecocq S, Chapman MJ, Rader DJ, Kontush A, Cuchel M.

J Clin Lipidol. 2017 Sep - Oct;11(5):1192-1200.e3. doi: 10.1016/j.jacl.2017.06.018. Epub 2017 Jul 8.

PMID:
28826666
15.

Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.

Zvintzou E, Lhomme M, Chasapi S, Filou S, Theodoropoulos V, Xapapadaki E, Kontush A, Spyroulias G, Tellis CC, Tselepis AD, Constantinou C, Kypreos KE.

J Lipid Res. 2017 Sep;58(9):1869-1883. doi: 10.1194/jlr.M077925. Epub 2017 Jul 12.

16.

Structure-function relationships in reconstituted HDL: Focus on antioxidative activity and cholesterol efflux capacity.

Cukier AMO, Therond P, Didichenko SA, Guillas I, Chapman MJ, Wright SD, Kontush A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Sep;1862(9):890-900. doi: 10.1016/j.bbalip.2017.05.010. Epub 2017 May 18.

PMID:
28529180
17.

Serum lipidomics reveals early differential effects of gastric bypass compared with banding on phospholipids and sphingolipids independent of differences in weight loss.

Kayser BD, Lhomme M, Dao MC, Ichou F, Bouillot JL, Prifti E, Kontush A, Chevallier JM, Aron-Wisnewsky J, Dugail I, Clément K.

Int J Obes (Lond). 2017 Jun;41(6):917-925. doi: 10.1038/ijo.2017.63. Epub 2017 Mar 10.

PMID:
28280270
18.

Poor glycemic control in type 2 diabetes enhances functional and compositional alterations of small, dense HDL3c.

Gomez Rosso L, Lhomme M, Meroño T, Dellepiane A, Sorroche P, Hedjazi L, Zakiev E, Sukhorukov V, Orekhov A, Gasparri J, Chapman MJ, Brites F, Kontush A.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Feb;1862(2):188-195. doi: 10.1016/j.bbalip.2016.10.014. Epub 2016 Nov 2.

PMID:
27815221
19.

Statin action enriches HDL3 in polyunsaturated phospholipids and plasmalogens and reduces LDL-derived phospholipid hydroperoxides in atherogenic mixed dyslipidemia.

Orsoni A, Thérond P, Tan R, Giral P, Robillard P, Kontush A, Meikle PJ, Chapman MJ.

J Lipid Res. 2016 Nov;57(11):2073-2087. Epub 2016 Aug 31.

20.

HDL-Targeting Therapeutics: Past, Present and Future.

Zakiev E, Feng M, Sukhorukov V, Kontush A.

Curr Pharm Des. 2017;23(8):1207-1215. doi: 10.2174/1381612822666161027153140. Review.

PMID:
27799042
21.

Lifestyle intervention enhances high-density lipoprotein function among patients with metabolic syndrome only at normal low-density lipoprotein cholesterol plasma levels.

Hansel B, Bonnefont-Rousselot D, Orsoni A, Bittar R, Giral P, Roussel R, Marre M, Mohammedi K, Bruckert E, Chapman MJ, Kontush A.

J Clin Lipidol. 2016 Sep-Oct;10(5):1172-81. doi: 10.1016/j.jacl.2016.05.008. Epub 2016 May 14.

PMID:
27678434
22.

Enhanced HDL Functionality in Small HDL Species Produced Upon Remodeling of HDL by Reconstituted HDL, CSL112: Effects on Cholesterol Efflux, Anti-Inflammatory and Antioxidative Activity.

Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Thérond P, Chapman MJ, Kontush A, Wright SD.

Circ Res. 2016 Sep 2;119(6):751-63. doi: 10.1161/CIRCRESAHA.116.308685. Epub 2016 Jul 19.

23.

Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis.

Botta E, Meroño T, Saucedo C, Martín M, Tetzlaff W, Sorroche P, Boero L, Malah V, Menafra M, Gómez Rosso L, Chapman JM, Kontush A, Soriano E, Brites F.

Atherosclerosis. 2016 Aug;251:438-444. doi: 10.1016/j.atherosclerosis.2016.06.009. Epub 2016 Jun 11.

PMID:
27344073
24.

Distinct Roles of Apolipoproteins A1 and E in the Modulation of High-Density Lipoprotein Composition and Function.

Filou S, Lhomme M, Karavia EA, Kalogeropoulou C, Theodoropoulos V, Zvintzou E, Sakellaropoulos GC, Petropoulou PI, Constantinou C, Kontush A, Kypreos KE.

Biochemistry. 2016 Jul 12;55(27):3752-62. doi: 10.1021/acs.biochem.6b00389. Epub 2016 Jun 29.

PMID:
27332083
25.

Phosphatidylserine in atherosclerosis.

Darabi M, Kontush A.

Curr Opin Lipidol. 2016 Aug;27(4):414-20. doi: 10.1097/MOL.0000000000000298. Review.

PMID:
27070078
26.

Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease.

Zanoni P, Khetarpal SA, Larach DB, Hancock-Cerutti WF, Millar JS, Cuchel M, DerOhannessian S, Kontush A, Surendran P, Saleheen D, Trompet S, Jukema JW, De Craen A, Deloukas P, Sattar N, Ford I, Packard C, Majumder Aa, Alam DS, Di Angelantonio E, Abecasis G, Chowdhury R, Erdmann J, Nordestgaard BG, Nielsen SF, Tybjærg-Hansen A, Schmidt RF, Kuulasmaa K, Liu DJ, Perola M, Blankenberg S, Salomaa V, Männistö S, Amouyel P, Arveiler D, Ferrieres J, Müller-Nurasyid M, Ferrario M, Kee F, Willer CJ, Samani N, Schunkert H, Butterworth AS, Howson JM, Peloso GM, Stitziel NO, Danesh J, Kathiresan S, Rader DJ; CHD Exome+ Consortium; CARDIoGRAM Exome Consortium; Global Lipids Genetics Consortium.

Science. 2016 Mar 11;351(6278):1166-71. doi: 10.1126/science.aad3517.

27.

Identifying new Risk Markers and Potential Targets: The Value of the Proteome.

Kontush A.

Cardiovasc Drugs Ther. 2016 Feb;30(1):13-8. doi: 10.1007/s10557-016-6656-3. Review.

PMID:
26931819
28.

Oxidative stress, HDL functionality and effects of intravenous iron administration in women with iron deficiency anemia.

Meroño T, Dauteuille C, Tetzlaff W, Martín M, Botta E, Lhomme M, Saez MS, Sorroche P, Boero L, Arbelbide J, Chapman MJ, Kontush A, Brites F.

Clin Nutr. 2017 Apr;36(2):552-558. doi: 10.1016/j.clnu.2016.02.003. Epub 2016 Feb 13.

PMID:
26926576
29.

Small, dense high-density lipoprotein 3 particles exhibit defective antioxidative and anti-inflammatory function in familial hypercholesterolemia: Partial correction by low-density lipoprotein apheresis.

Hussein H, Saheb S, Couturier M, Atassi M, Orsoni A, Carrié A, Therond P, Chantepie S, Robillard P, Bruckert E, Chapman MJ, Kontush A.

J Clin Lipidol. 2016 Jan-Feb;10(1):124-33. doi: 10.1016/j.jacl.2015.10.006. Epub 2015 Oct 17.

PMID:
26892129
30.

D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.

Valleix S, Verona G, Jourde-Chiche N, Nédelec B, Mangione PP, Bridoux F, Mangé A, Dogan A, Goujon JM, Lhomme M, Dauteuille C, Chabert M, Porcari R, Waudby CA, Relini A, Talmud PJ, Kovrov O, Olivecrona G, Stoppini M, Christodoulou J, Hawkins PN, Grateau G, Delpech M, Kontush A, Gillmore JD, Kalopissis AD, Bellotti V.

Nat Commun. 2016 Jan 21;7:10353. doi: 10.1038/ncomms10353.

31.

[The biological activity of high-density lipoprotein fractions and their role in the development of cardiovascular diseases].

Babintseva YD, Camont L, Chapman J, Lhomme M, Karagodin VP, Kontush A, Orekhov AN.

Ter Arkh. 2016;88(9):111-118. doi: 10.17116/terarkh2016889111-118. Review. Russian.

PMID:
28635814
32.

Therapeutic applications of reconstituted HDL: When structure meets function.

Darabi M, Guillas-Baudouin I, Le Goff W, Chapman MJ, Kontush A.

Pharmacol Ther. 2016 Jan;157:28-42. doi: 10.1016/j.pharmthera.2015.10.010. Epub 2015 Nov 10. Review.

PMID:
26546991
33.

HDL particle number and size as predictors of cardiovascular disease.

Kontush A.

Front Pharmacol. 2015 Oct 5;6:218. doi: 10.3389/fphar.2015.00218. eCollection 2015. Review.

34.

Proteomic and lipidomic analyses of paraoxonase defined high density lipoprotein particles: Association of paraoxonase with the anti-coagulant, protein S.

Moren X, Lhomme M, Bulla A, Sanchez JC, Kontush A, James RW.

Proteomics Clin Appl. 2016 Mar;10(3):230-8. doi: 10.1002/prca.201500062. Epub 2015 Dec 8.

PMID:
26358807
35.

Dysfunctional HDL and atherosclerotic cardiovascular disease.

Rosenson RS, Brewer HB Jr, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Kontush A, Tall AR, Webb NR.

Nat Rev Cardiol. 2016 Jan;13(1):48-60. doi: 10.1038/nrcardio.2015.124. Epub 2015 Sep 1. Review.

36.

Can phosphatidylserine enhance atheroprotective activities of high-density lipoprotein?

Darabi M, Kontush A.

Biochimie. 2016 Jan;120:81-6. doi: 10.1016/j.biochi.2015.06.022. Epub 2015 Jun 30. Review.

PMID:
26141129
37.

Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: Relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A.

Rached F, Lhomme M, Camont L, Gomes F, Dauteuille C, Robillard P, Santos RD, Lesnik P, Serrano CV Jr, Chapman MJ, Kontush A.

Biochim Biophys Acta. 2015 Sep;1851(9):1254-61. doi: 10.1016/j.bbalip.2015.05.007. Epub 2015 May 30.

PMID:
26037829
38.

HDL particle subpopulations: Focus on biological function.

Rached FH, Chapman MJ, Kontush A.

Biofactors. 2015 Mar-Apr;41(2):67-77. doi: 10.1002/biof.1202. Epub 2015 Mar 23. Review.

PMID:
25809447
39.

HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export.

Du XM, Kim MJ, Hou L, Le Goff W, Chapman MJ, Van Eck M, Curtiss LK, Burnett JR, Cartland SP, Quinn CM, Kockx M, Kontush A, Rye KA, Kritharides L, Jessup W.

Circ Res. 2015 Mar 27;116(7):1133-42. doi: 10.1161/CIRCRESAHA.116.305485. Epub 2015 Jan 14. Erratum in: Circ Res. 2015 Jul 17;117(3):e40.

40.

Functionality of HDL: antioxidation and detoxifying effects.

Karlsson H, Kontush A, James RW.

Handb Exp Pharmacol. 2015;224:207-28. doi: 10.1007/978-3-319-09665-0_5. Review.

PMID:
25522989
41.

Structure of HDL: particle subclasses and molecular components.

Kontush A, Lindahl M, Lhomme M, Calabresi L, Chapman MJ, Davidson WS.

Handb Exp Pharmacol. 2015;224:3-51. doi: 10.1007/978-3-319-09665-0_1. Review.

42.

Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation.

Gómez Rosso L, Lhomme M, Meroño T, Sorroche P, Catoggio L, Soriano E, Saucedo C, Malah V, Dauteuille C, Boero L, Lesnik P, Robillard P, John Chapman M, Brites F, Kontush A.

Atherosclerosis. 2014 Dec;237(2):652-60. doi: 10.1016/j.atherosclerosis.2014.09.034. Epub 2014 Oct 18. Erratum in: Atherosclerosis. 2015 Jun;240(2):468.

PMID:
25463101
43.

Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity.

Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, Bedossa P, Kontush A, Clement K, Dugail I, Tordjman J.

J Hepatol. 2015 Apr;62(4):905-12. doi: 10.1016/j.jhep.2014.11.002. Epub 2014 Nov 8.

PMID:
25450212
44.

Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload.

Meroño T, Brites F, Dauteuille C, Lhomme M, Menafra M, Arteaga A, Castro M, Saez MS, Ballerga EG, Sorroche P, Rey J, Lesnik P, Sordá JA, Chapman MJ, Kontush A, Daruich J.

Clin Sci (Lond). 2015 May;128(9):609-18. doi: 10.1042/CS20140300.

PMID:
25442240
45.

Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome.

Rached F, Santos RD, Camont L, Miname MH, Lhomme M, Dauteuille C, Lecocq S, Serrano CV Jr, Chapman MJ, Kontush A.

J Lipid Res. 2014 Dec;55(12):2509-20. doi: 10.1194/jlr.M051631. Epub 2014 Oct 23.

46.

Adipocyte ATP-binding cassette G1 promotes triglyceride storage, fat mass growth, and human obesity.

Frisdal E, Le Lay S, Hooton H, Poupel L, Olivier M, Alili R, Plengpanich W, Villard EF, Gilibert S, Lhomme M, Superville A, Miftah-Alkhair L, Chapman MJ, Dallinga-Thie GM, Venteclef N, Poitou C, Tordjman J, Lesnik P, Kontush A, Huby T, Dugail I, Clement K, Guerin M, Le Goff W.

Diabetes. 2015 Mar;64(3):840-55. doi: 10.2337/db14-0245. Epub 2014 Sep 23.

47.

HDL-mediated mechanisms of protection in cardiovascular disease.

Kontush A.

Cardiovasc Res. 2014 Aug 1;103(3):341-9. doi: 10.1093/cvr/cvu147. Epub 2014 Jun 15. Review.

PMID:
24935434
48.

HDL-targeted therapies: progress, failures and future.

Kingwell BA, Chapman MJ, Kontush A, Miller NE.

Nat Rev Drug Discov. 2014 Jun;13(6):445-64. doi: 10.1038/nrd4279. Epub 2014 May 23. Review.

PMID:
24854407
49.

An overview of the new frontiers in the treatment of atherogenic dyslipidemias.

Rached FH, Chapman MJ, Kontush A.

Clin Pharmacol Ther. 2014 Jul;96(1):57-63. doi: 10.1038/clpt.2014.85. Epub 2014 Apr 11. Review.

PMID:
24727469
50.

Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities.

Camont L, Lhomme M, Rached F, Le Goff W, Nègre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A.

Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2715-23. doi: 10.1161/ATVBAHA.113.301468. Epub 2013 Oct 3.

PMID:
24092747

Supplemental Content

Loading ...
Support Center